Recent advances in antifungal pharmacotherapy for invasive fungal infections

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 253-268

  Gallagher, Jason C ^a   MacDougall, Conan ^b   Dodds Ashley, Elizabeth S ^c,d   Perfect, John R ^c  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Campbell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CHITIN SYNTHASE; CYCLODEXTRIN; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GLUCAN SYNTHASE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; PLACEBO; POLY(HEXAMETHYLENEBIGUANIDE); POSACONAZOLE; PRODRUG; RAVUCONAZOLE; RIFAMPICIN; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CRYPTOCOCCOSIS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SOLUTION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FEVER; FUNGAL MENINGITIS; HISTOPLASMOSIS; HUMAN; INFUSION REACTION; LIVER DYSFUNCTION; LIVER TOXICITY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; PHLEBITIS; REVIEW; SIDE EFFECT; SPOROTRICHOSIS; VISCERAL LEISHMANIASIS; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

EID: 2942590766     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.253     Document Type: Review

References (131)

1. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33(2), 177-186 (2001).
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002).
3. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisted. Clin. Infect. Dis. 37(9), 1172-1177 (2003).
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Di. 32(3), 358-366 (2001).
5. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 123(Suppl. 5), 500-503 (2003).
6. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. 33(10), 1692-1696 (2001).
7. Munoz P, Fernandez-Turegano CP, Alcala L et al. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn. Microbiol. Infect. Dis. 44(2), 163-167 (2002).
8. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233(4), 542-548 (2001).
9. Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 28(12), 1708-1717 (2002).
10. Koh LP, Kurup A, Goh YT et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am. J. Hematol. 71(4), 260-267 (2002).
11. Oliveira JS, Kerbauy FR, Colombo AL et al. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz. J. Med. Biol. Res. 35 (7), 789-798 (2002).
12. Liu W, Lewis RE, May GS, Kontoyiannis DP. Pre-exposure of A. fumigatus to fluconazole (FLU) induces tolerance to itraconazole (Itra) in vivo. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemothapy 11, USA, 14-17 September 2003.
13. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 39(1), 40-44 (1995).
14. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 696-709 (2000)
15. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29(6), 1402-1407 (1999).
16. Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J. Pharm. Pharm. Sci. 6(1), 67-83 (2003).
17. Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr. Clin. Top. Infect. Dis. 20, 1-23 (2000).
18. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27(3), 603-618 (1998).
19. Deray G. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 49(Suppl.), 41 (2002).
20. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother 45(12), 3487-3496 (2001).
21. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35(4), 359-366 (2002).
22. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340(10), 764-771 (1999).
23. Fujisawa Corporation. AmBisome package insert. Deerfield, IL, USA (2003).
24. Enzon Corporation. Abelcet package insert. Bridgewater, NJ, USA (2003).
25. InterMune Corporation. Amphotec package insert. Brisbane, CA, USA (2003).
26. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin. Infect. Dis. 35, 891-895 (2002).
27. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31(5), 1155-1163 (2000).
28. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma 40(5-6), 511-520 (2001).
29. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy and tolerability. Transpl. Infect. Dis. 1(4), 273-283 (1999).
30. Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int. J. Antimicrob. Agents 17(3), 161-169 (2001).
31. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37(3), 415-425 (2003).
32. Barrett JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25(5), 1295-1320 (2003).
33. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 662-678 (2000).
34. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic anlysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18(12), 2476-2483 (2000).
35. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 2(6), 500-508 (1992).
36. Kuti JL, Kotapati S, Williams P et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September 2002.
37. Speich R, Dutly A, Naef R et al. Tolerability, safety and efficacy of conventional ampohtericin B administered by 24 hour infusion to lung transplant recipients. Swiss Med. Wkly 132, 455-458 (2002).
38. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomized controlled trial. Br. Med. J. 332, 1-6 (2001).
39. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36, 943-951 (2004).
40. Galgiani JN, Ampel NM, Catanzaro A et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 658-661 (2000).
41. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000).
42. Janssen Pharmaceutical Products. Sporanox® (itraconazole) package insert. Raritan, NJ, USA (2002).
43. Boogaerts MM, Winston DJM, Bow EJM et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad spectrum antibacterial therapy: a randomized, controlled trial. Ann. Intern. Med. 135(6), 412-422 (2001).
44. Denning DW, Lee JY, Hostetler JS et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97(2), 135-144 (1994).
45. Harousseau JL, Dekker AW, Stamatoullas-Bastard A et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob. Agents Chemother 44(7), 1887-1893 (2000).
46. Barone JA, Moskovitz BL, Guarnieri J et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. 42(7), 1862-1865 (1998).
47. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann. Pharmacother. 35(6), 720-729 (2001).
48. Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin. Proc. 74(1), 78-100 (1999).
49. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36(9), 1122-1131 (2003).
50. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39(3), 954-958 (2001).
51. Pfizer, Inc. Vfena® (voriconazole) package insert. New York, NY, USA (2002).
52. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002).
53. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346(4), 225-234 (2002).
54. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and vonconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46(6), 1723-1727 (2002).
55. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33(9), 1447-1454 (2001).
56. Troke PF, Espinel-Ingroff A, Johnson EM, Schlamm H. Susceptibility of moulds from two open, randomized, comparative studies of the efficacy and safety of voriconazole (VORI) versus amphotericin B (AMB) in the treatment of acute invasive aspergillosis (AIA) in immunocompromised patients. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 16-19 December (2001).
57. Potoski BA, Brown J. The safety of voriconazole. Clin. Infect. Dis. 35(10), 1273-1275 (2002).
58. Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin. Infect. Dis. 37(6), 828-830 (2003).
59. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34(5), 563-571 (2002).
60. Greenberg RN, Anstead G, Herbrecht R et al. Posaconazole experience in the treatment of zygomycosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 14-17 September 2003.
61. Capilla J, Yustes C, Mayayo E et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrobial Agents Chemother. 47(6), 1948-1951 (2003).
62. Hoang A. Caspofungin acetate: an antifungal agent. Am. J. Health-Syst. Pharm. 58(13), 1206-1214 (2001).
63. Merck and Co. Cancidas® (caspofungin acetate) package insert. Whitehouse Station, NJ, USA (2001).
64. Maertens J, Raad I, Petrikkos G et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractor (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September (2002).
65. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33(9), 1529-1535 (2001).
66. Villanueva A. Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113(4), 294-299 (2002).
67. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
68. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin. Infect. Dis. 32(9), 1249-1272 (2001).
69. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46(6), 1773-1780 (2002).
70. Bachmann SP, VandeWille K, Ramage G et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46(11), 3591-3596 (2002).
71. Schinabeck MK, Chandra J, Mukherjee PK, Ghannoum MA. Characterization and susceptibility of echinocandin resistant Candida albicans biofilms. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherap. IL, USA, 14-17 September 2003.
72. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. 4(1), 25-30 (2002).
73. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 182(6), 1791-1795 (2000).
74. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY-303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36(10), 2950-2956 (1998).
75. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int. J. Clin. Pract. 55(9), 633-638 (2001).
76. Bennett JE, Dismukes WE, Durra RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 301(3), 126-131 (1979).
77. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother 39(9), 1907-1912 (1995).
78. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36(10), 1221-1228 (2003).
79. Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 35(7), 1329-1333 (1991).
80. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea-pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46(8), 2564-2568 (2002).
81. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187(12), 1834-1843 (2003).
82. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and safety of the caspofungin/liposomal amphotericin B (CAS/LipoAMB) combination in possible or documented invasive aspergillosis (IA) in patients (Pts) in hematological malignancies. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September 2002.
83. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14(4), 643-658 (2001).
84. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35(8), 982-989 (2002).
85. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 688-695 (2000).
86. Chapman SW, Bradsher RW Jr, Campbell GD Jr, Pappas PG, Kauffman CA. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 679-683 (2000).
87. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 684-687 (2000).
88. Walsh TJ, Sable C, Depauw B et al. A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 14-17 September 2003.
89. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47(3), 1068-1071 (2003).
90. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy CA, USA, 27-30 September (2002).
91. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob. Agents Chemother. 47(7), 2373-2375 (2003).
92. Roling EE, Klepser ME, Wasson A et al. Antifungal activities of fluconazole, caspofungin (MK0991) and anidulafungin (LY 303366) alone and in combination against Candidi spp. and Crytococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43(1), 13-17 (2002).
93. Waldrep TW, Keiser P, Ware A et al, Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy CA, USA, 27-30 September (2002).
94. Edlind TD, Katiyar SK Caspofungin-tolerant mutants of Candida albicans and Candida glabrata. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy IL, USA, 14-17 September (2003).
95. Kartsonis N, DiNubile MJ, Bartizal K et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr. 31(2), 183-187 (2002).
96. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. 50(1), 119-123 (2002).
97. Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 39(Suppl. 6) 102-106 (1996).
98. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Monzon A, Rodriguez-Tudela JL. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur. J. Clin. Microbiol. Infect. Dis. 18(6), 432-435 (1999).
99. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis. 31(1), 297-300 (1998).
100. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of voriconazole, posaconazole and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J. Clin. Microbiol. 41(1), 78-83 (2003).
101. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22(11), 651-655 (2003).
102. Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 44(7), 253-260 (2001).
103. Drew RH, Palmer SM, Davis R, Perfect JR. Invasive fungal infections (IFIs) in lung transplant recipients (LTR) receiving prophylactic aerosolized amphotericin B (aAmB) formulations. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 27-30 September (2002).
104. Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20(7), 1898-1906 (2002).
105. Kami M, Fukui T, Ogawa S et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin. Infect. Dis. 33(9), 1504-1512 (2001).
106. Pinker S. ORs dosed after Aspergillus discovered at Royal Vic. Can. Med. Assoc. J. 164(9), 1333 (2001).
107. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin. Infect. Dis. 33(9), 1546-1548 (2001).
108. Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis. 34(6), 780-789 (2002).
109. Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin. Infect. Dis. 37(1), 17-25 (2003).
110. Caillot D, Bassaris H, McGeer A et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease or AIDS. Clin. Infect. Dis. 33(8), e83-e90 (2001).
111. Gentina T, De Botton S, Alfandari S, Delomez J, Jaillard S, Leroy O. Combination antifungals for treatment of pulmonary invasive aspergillosis (IS) refractory to amphotericin B (AmB) in leukaemia patients. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy CA, USA, 27-30 September 2002.
112. Kontoyiannis DP, Lewis RE, May GS, Albert ND, Raad II. Sequential exposure of A. fumigatus to itraconazole (ITRA) and caspofungin (CAS): evidence of enhanced in vitro activity of this combination. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy CA, USA, 27-30 September 2002.
113. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: 10 years experience at a cancer center and implications for management. Blood 90(3), 999-1008 (1997).
114. Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. 37(2), 221-229 (2003).
115. Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin. Pharmacother: 4(2), 147-164 (2003).
116. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. 35(8), 909-920 (2002).
117. Musa MO, Al Eisa A, Halim M et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br. J. Haematol. 108(3), 544-548 (2000).
118. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41(8), 1835-1836 (1997).
119. Apostolidis J, Bouzani M, Platsouka E et al. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin. Clin. Infect. Dis. 36(10), 1349-1350 (2003).
120. Reis A, Sundmacher R, Tintelnot K et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthalmol. 84(8), 932-933 (2000).
121. Consigny S, Dhedin N, Datry A et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin. Infect. Dis. 37(2), 311-313 (2003).
122. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl.10) 7-10 (2002).
123. Meletiadis J, Meis JF, Mouton JW et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. 46(1), 62-68 (2002).
124. Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl. Infect. Dis. 3(4), 189-194 (2001).
125. Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 4(4), 212-217 (2002).
126. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetant child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J. Clin. Microbiol. 41(8), 3981-3985 (2003).
127. Studahl M, Backteman T, Stalhammer F, Chryssanthou E, Petrini B. Bone and joint infection after traumatic implantation of Scedosporim prolificans treated with voriconazole and surgery. Acta Paediactr. 92(8), 980-982 (2003).
128. Deresinski SC, Stevens DA. Caspofungin. Clin. Infect. Dis. 36(11), 1445-1457 (2003).
129. Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36(11), 1488-1491 (2003).
130. Jacobs P, Wood L, Du TA, Esterhuizen K. Eradication of invasive mucormycosis-effectiveness of the Echinocandin FK463. Hematology. 8(2), 119-123 (2003).
131. Larkin JA, Montero JA, Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect. Med. 20(4), 201-206 (2003).